Please assess the completion status of the following clinical trial:

Trial Title: 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must meet all of the following clinical criteria for MCI due to AD or mild AD and must have:~* A Clinical Dementia Rating (CDR)-Global Score of 0.5.~* Objective evidence of cognitive impairment at screening~* An MMSE score between 24 and 30 (inclusive)~* Must have a positive amyloid Positron Emission Tomography (PET) scan~* Must consent to apolipoprotein E (ApoE) genotyping~* If using drugs to treat symptoms related to AD, doses must be stable for at least 8 weeks prior to screening visit 1~* Must have a reliable informant or caregiver~Key Exclusion Criteria:~* Any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the subject's cognitive impairment~* Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year~* Clinically significant unstable psychiatric illness in past 6 months~* History of unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within 1 year prior to Screening~* Indication of impaired renal or liver function~* Have human immunodeficiency virus (HIV) infection~* Have a significant systematic illness or infection in past 30 days~* Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities~* Any contraindications to brain magnetic resonance imaging (MRI) or PET scans~* Alcohol or substance abuse in past 1 year~* Taking blood thinners (except for aspirin at a prophylactic dose or less)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): Monthly intravenous (IV) infusions
- High Dose (Type: EXPERIMENTAL): Monthly intravenous (IV) infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).